Melanoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• A written consent form must be signed by the participant or their legally authorised representative before any study procedures begin
• Adults aged 18 or older of any gender identity or racial/ethnic background are eligible
• The participant must have a confirmed diagnosis of primary skin melanoma (including acral melanoma, which affects the palms, soles, or nail areas), verified through a tissue sample examination
• The melanoma must meet one of two specific staging criteria: either an early-stage (Stage IA) melanoma thicker than 0.5 mm with at least one higher-risk feature (such as a high rate of cell division, patient age of 42 or younger, involvement of blood or lymph vessels, or location on the head or neck), or a Stage IB melanoma — and if the original biopsy did not clearly show the full thickness of the melanoma, a re-biopsy must be done to confirm this
• The melanoma must be classified as "low risk" on a specific genetic test called the Merlin Assay (by SkylineDx)
• The surgical treatment must take place within 120 days of the original diagnostic biopsy
• The participant must have a general health status that meets a standard medical activity scale (meaning they are reasonably able to carry out daily activities), confirmed by the treating doctor
• People with a history of another cancer may be eligible, as long as that cancer or its treatment is unlikely to affect the safety or results of this study (confirm with trial site)
• People with a history of HIV infection may be eligible
• The participant must be able to speak, read, and write in English or Spanish

Who may not be able to join:

• People whose melanoma diagnosis is uncertain — for example, those with a severely abnormal mole or an unclear melanocytic growth that may or may not be cancerous
• People who have already had wide local excision surgery (a procedure to remove the melanoma along with a surrounding margin of skin) at the site of the melanoma
• People whose melanoma is of a specific type called "pure desmoplastic melanoma," meaning more than 90% of the tumour is made up of this particular cell type (melanomas with less than 90% of this type may still be eligible — confirm with trial site)
• People with mucosal melanoma (found in areas like the mouth or nose) or ocular melanoma (found in the eye), as these types require different surgical approaches
• People who have any physical, imaging, or laboratory evidence that the melanoma has spread to nearby or distant areas of the body
• People whose cancer is known or suspected to have spread beyond the original site, as this trial focuses on localised (non-spread) disease
• People who have previously had surgery to remove or examine the lymph nodes near the melanoma site, including a sentinel lymph node biopsy
• People for whom radiation therapy to the melanoma site is planned after surgery
• People who are unwilling or unable to follow the study procedures

Important: Always verify eligibility with the trial site directly before applying.